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Background: Bacteria expressing phosphorylcholine (ChoP) co-opt host-expressed platelet-
activating factor receptor (PAFR) to adhere to lower airway cells. Cigarette smoke and rhino-
virus (RV) infection upregulate PAFR-dependent bacterial adhesion to airway cells in vitro, and
in healthy adults smoking increases the proportion of PAFR positive bronchial epithelial cells.
To date the effect of chronic obstructive pulmonary disease (COPD) on smoke-induced PAFR is
unknown. We therefore sought to test the hypothesis that bronchial PAFR mRNA expression is
increased in smokers with chronic obstructive pulmonary disease (COPD), and further increases
after RV infection.
Methods: Endobronchial biopsies were obtained by fibreoptic bronchoscopy from healthy non-
smokers, smokers without airway obstruction, and smokers with COPD, before and after infec-
tion with rhinovirus (RV) serotype 16. Endobronchial PAFR mRNA expression was assessed by
quantitative PCR and expressed as a ratio of glyceraldehyde-3-phosphate dehydrogenase.
The distribution of PAFR was assessed by immunohistochemistry.
Results: Baseline PAFR mRNA expression was increased (p < 0.05) in smokers (n Z 16), and
smokers with COPD (n Z 14) compared with non-smokers (n Z 18). In RV16 infected subjects
there was no increase in PAFR mRNA expression in either non-smokers (n Z 9), smokers
(n Z 8), or smokers with COPD (n Z 7). PAFR immunoreactivity in all 3 groups was predomi-




Bronchial PAFR in COPD 899Conclusions: Endobronchial PAFR mRNA is increased in both smokers without airway obstruc-
tion and smokers with COPD. We found preliminary evidence that RV16 infection does not in-
crease PAFR mRNA expression in either smokers or smokers with COPD.
ª 2014 Elsevier Ltd. All rights reserved.Background
Exacerbations of chronic obstructive pulmonary disease
(COPD) result from an interaction between external factors
such as smoking and viral infection, and host innate im-
mune responses [1]. Wilkinson et al. [2] for example, re-
ported that 20% of COPD exacerbations are associated with
a rhinovirus (RV) infection, and patients with both RV and
bacterial infection (predominately Haemophilus influenzae
and/or Streptococcus pneumoniae) have increased airway
inflammation and poorer clinical outcomes [2,25]. Smoking
not only causes COPD, but also increases vulnerability to
airway bacterial infection and invasive pneumococcal dis-
ease in its own right [3,4]. A putative mechanism for
increased vulnerability of the lower airway to bacterial
infection is an increased capacity of airway cells to support
bacterial adhesion. In vitro studies suggest that for phos-
phorycholine (ChoP)-expressing bacteria such as S. pneu-
moniae [5,6], and H. influenzae [6,7], adhesion is enhanced
by increased expression of platelet-activating factor re-
ceptor (PAFR) on host cells. During the resulting interac-
tion, bacterial ChoP is a molecular mimic of PAF. Thus
ChoP-expressing bacteria have the capacity to both
adhere to PAFR, and to move across the cell membrane as
the receptor is internalised.
A wide range of stimuli have been reported to increase
PAFR-dependent adhesion of ChoP-expressing bacteria to
airway epithelial cells. These include acid [8], interleukin
1a [5], RV infection [9], and cigarette smoke [10,14]. But to
date, data on PAFR expression in the human lung are
limited. In a recent pilot study, we found an increased
proportion of PAFR-positive epithelial cells in bronchial
biopsies from smokers with normal lung function compared
with non-smokers [10]. By contrast, in the only other study
using human lung tissue, Shirasaki et al. [11] reported
decreased PAFR mRNA expression in peripheral lung biopsy
specimens in 4 smokers compared with 8 controls and no
PAFR mRNA expression on airway epithelial cells e the
major site for clinically relevant bacterial adhesion. How-
ever in human turbinates, PAFR immunoreactivity has been
reported in both the submucosal glands and epithelial cells
[12].
To date, the effect of smoking on airway PAFR expres-
sion in COPD is unknown. We hypothesised that i) PAFR is
increased in bronchial biopsies of current smokers with
COPD compared with healthy controls, and ii) PAFR
expression is increased by RV infection. In the present
study, we sought to test this hypothesis using stored
endobronchial biopsies from a study of healthy subjects,
smokers with normal lung function, and smokers with COPD
[13].Methods
Subjects
Endobronchial biopsies were obtained from an experimental
RV infection study that recruited human volunteers in London
(UK).Dataonbacterial infection, symptomsandantimicrobial
peptides have been previously reported [13]. Three groups
were studied; i) healthy non-smokers (controls), ii) smokers
without airway obstruction, and iii) smokers with moderate
COPD (Gold stage II). Bronchoscopy, endobronchial biopsy,
bronchoalveolar lavage, and induced sputumwerecarriedout
at baseline before RV serotype 16 (RV16) inoculation as pre-
viously described [13]. Endobronchial biopsywas repeated on
day 7 after RV inoculation. Informed consent was obtained
from all subjects (Research Ethics Committee approval 07/
H0712/138, and 11/LO/0400).
Rhinovirus inoculation and detection
Ten tissue culture infective doses 50% of RV16 were diluted
in a total volume of 1 ml of 0.9% saline and inoculated in
both nostrils using an atomizer (No. 286; DeVilbiss Co.,
Heston, UK). Rhinovirus infection was defined as; either a
positive RV culture or qPCR, in nasal lavage/sputum/bron-
choalveolar lavage, or RV seroconversion defined as a titre
of serum neutralising antibodies to RV of at least 1:4 at
6 wk. Serology was performed at screening and 6 wk post-
infection by microneutralisation test for neutralising anti-
body to rhinovirus. Infection with viruses other than RV was
excluded by testing nasal lavage samples at baseline and at
the peak of upper respiratory symptoms with PCR.
Endobronchial biopsy
Subjects were premedicated with nebulised salbutamol
(2.5 mg) and intravenous midazolam (2e10 mg). Lignocaine
gel and solutions (1e4%) were used for topical anesthesia.
Bronchoscopy was performed using an Olympus BF 1T20
(Olympus Optical Co., Tokyo, Japan), and biopsies were
taken from the lower lobe subcarinae and were snap frozen
in liquid nitrogen and stored at 70 C for analysis of PAFR
mRNA.
PAFR mRNA
Endobronchial biopsy tissue was homogenised and the RNA
extracted using the RNAeasy kit (Qiagen, Crawley, UK).
First strand cDNA was synthesised using SuperScript VILO
master mix according to manufacturer’s instructions (Life
Table 1 Subject Demographics and endobronchial PAFR mRNA expression.
Non-smokers Smokers Smokers with COPD
n 18 16 14
Age (yr) 59.2  1.6 54.3  1.8 59.6  2.2
Body mass index (kg m2) 25.2  1.0 27.1  0.9 25.7  1.1
Females (n) 9 7 5
Smoking pack years (n) 0 33.25  2.21 39.35  2.24
FEV1 (% predicted) 112.3  4.4 102.9  3.4 64  3.4
FVC (% predicted) 124.4  4.8 117.5  3.0 95.0  3.5
FEV1/FVC 73.9  1.2 71.6  1.1 54.3  2.7
Baseline (day 0) PAFR mRNA expression 1.17  0.01 1.22  0.01a 1.23  0.01a
n Z 18 n Z 16 n Z 14
PAFR mRNA expression at day 7 in
rhinovirus-infected subjects
1.19  0.01 1.16  0.03 1.25  0.03
(n Z 9) (n Z 8) (n Z 7)
Data are summarised as mean (standard error of mean). FEV1; forced expiratory volume in 1 s, FVC; forced vital capacity. PAFR;
platelet-activating factor receptor mRNA expression was determined by qPCR and expressed relative to the housekeeping gene glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH).
a p < 0.05 vs. non smokers by unpaired t test. There is no difference in PAFR between the 3 groups at day 7.
900 R. Suri et al.technologies, Paisley, UK). mRNA transcript level of PAFR
and the housekeeping gene glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) were determined by quantitative
real-time PCR using an ABI 7500 real-time PCR system
(Applied Biosystems, Warrington, UK) with TaqMan primer
and probe sets Hs00265399_S1 (PAFR) and Hs02758991_g1
(GAPDH). RT-PCR reactions were carried out in triplicate.
The PAFR to housekeeping gene ratio was generated for
each sample.Figure 1 Baseline platelet-activating factor receptor (PAFR)Immunohistochemistry
Antigen retrieval was carried out in on 3 mm paraffin wax
embedded sections dried down overnight at 60 C. Sec-
tions were dewaxed through graded alcohols and then
placed in an EDTA buffer of pH8.1 and microwaved at full
power for 35 min. The slides were then transferred to a
DAKO Autostainer where they were treated with a 3%
peroxidase block followed by the Vector R.T.U Vectastain
Kit (PK-7200), according to manufacturer’s recommenda-
tions. The working dilution of the human anti-PAFR
monoclonal antibody CAY160600 (Cayman Chemical,
Cambridge Bioscience, UK) was 1:100 and the incubation
time was 40 min. The signal was visualised using DAKO
DAB þ Chromogen solution (K3468) applied for 5 min. A
Gills haematoxylin nuclei counterstain was used for 2 min
and differentiated accordingly. A negative control using
tonsil tissue without the anti-PAFR antibody showed no
non-specific DAB signal.mRNA expression in endobronchial tissue in non-smokers,
smokers without airway obstruction, and smokers with COPD.
PAFR mRNA expression was measured by quantitative PCR and
expressed relative to the house-keeping gene glyceraldehyde-
3-phosphate dehydrogenase (GAPDH). PAFR is increased in
both smokers and smokers with COPD * p < 0.05 vs. non-
smokers, by unpaired t test and Dunnett’s multiple compari-
sons test. There is no difference in PAFR mRNA between
smokers and smokers with COPD (p Z NS, Dunnett’s multiple
comparisons test). Bar represents mean.Statistical analysis
Data are summarised as mean (SEM). Differences were
analysed by t test and Dunnett’s multiple comparisons test.
Correlations were expressed by Pearson correlation coeffi-
cient (r). Analyses were performed using GraphPad Prism
version 6.00b for Mac (GraphPad Software, San Diego, CA).
Differences were considered significant at p < 0.05.Results
Stored endobronchial tissue for PAFR mRNA at baseline (i.e.
pre-RV infection) was available from 18 non-smokers, 16
smokers, and 14 smokers with COPD (Table 1). Baseline
paraffin-embedded samples for PAFR immunostaining was
limited to 7 controls, 7 smokers, and 7 smokers with COPD.
There was no significant difference in age or body mass
index between the 3 groups (Table 1). In subjects who
developed a RV16 infection, paired baseline and day 7
(post-infection) biopsies were available from 9 non-
smokers, 8 smokers, and 7 smokers with COPD.
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to the GADPH housekeeping gene was increased in both
smokers and smokers with COPD (p < 0.05 vs. non smokers,
Fig. 1, Table 1). There was no difference in PAFR mRNA
expression between smokers and smokers with COPD
(p Z NS, Dunnett’s multiple comparisons test), and no
significant correlation between baseline PAFR mRNA
expression and pack years in either smokers, or smokers
with COPD.
PAFR-positive pseudostratified airway epithelial cells
were present in all 21 paraffin-embedded baseline sections
(Fig. 2(A)). Furthermore, PAFR-positive goblet cells were
prominent in both smokers and smokers with COPD
(Fig. 2(B)). PAFR-positive cells in bronchial submucosal
glands were also found in all 10 subjects where bronchial
submucosal glands were included in the section (controls
nZ 4, smokers nZ 3, and smoking with COPD nZ 3). PAFR
positivity of other cells, such as smooth muscle cells, wasFigure 2 A. Platelet-activating factor receptor (PAFR) staining
subject. PAFR expression is predominately limited to normal airwa
activating factor receptor (PAFR) expression (brown) in an endobr
PAFR positive goblet cells at the bronchial air-tissue interface (arr
receptor (PAFR) expression of bronchial mucosal glands (arrow) in
resents 100 microns. D. Comparison of platelet-activating factor re
an area of more normal epithelium (N) in a smoking subject. Bar re
colour in this figure legend, the reader is referred to the web verseither minimal or absent (Fig. 2(A) and (B)). PAFR immu-
nostaining in smokers and smokers with COPD was not
uniform since expression was lower in areas of squamous
metaplasia (Fig. 2(D)). Squamous metaplasia was not found
in healthy controls. The small number of samples available,
and the patchy nature of staining precluded quantitation of
PAFR immunoreactivity by image analysis.
Rhinovirus infection did not increase PAFR mRNA
expression in either non-smokers, smokers, or smokers with
COPD (Fig. 3, p Z NS, paired t test). Cross-sectional anal-
ysis in RV-infected subjects at day 7 showed no difference
in PAFR mRNA between the groups (Fig. 4, Table 1).Discussion
In this study we sought to assess the hypothesis that
endobronchial PAFR mRNA expression is increased in(brown) in endobronchial biopsy tissue from a non-smoking
y epithelium (arrow). Bar represents 100 microns. B Platelet-
onchial biopsy from a smoking subject with COPD. There are
ow). Bar represents 100 microns. C. Platelet-activating factor
an endobronchial biopsy from a smoker with COPD. Bar rep-
ceptor expression in an area of squamous metaplasia (SM) with
presents 100 microns. (For interpretation of the references to
ion of this article.)
Figure 3 Paired change in endobronchial platelet-activating
factor receptor (PAFR) mRNA expression between baseline and
day 7 post-inoculation in subjects who developed a rhinovirus
infection; (A) non-smokers, (B) smokers, (C) smokers with
COPD. PAFR mRNA is expressed relative to GAPDH. PAFR mRNA
expression did not change in any group (pZ NS, paired t test).
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our previous data from healthy smokers [10], we found
increased PAFR mRNA expression in both smokers and
smokers with COPD. There was no difference in PAFR mRNA
between smokers with COPD and smokers without airway
obstruction, suggesting that smoking, and not COPD is the
major stimulus for PAFR expression in vivo. Indeed epide-
miological studies suggest that, exposure to cigarette
smoke is a major risk factor for invasive pneumococcal
disease in immunocompetent adults [4]. We focused onPAFR, since animal and in vitro models suggest that
increased epithelial PAFR expression increases vulnerability
to bacterial infection in both the lung [5,15,16] and the gut
[17]. But to date the evidence that PAFR is expressed on
airway cells in vivo is contradictory. On one hand, Shirasaki
et al. [11] using in situ hybridisation reported no evidence
of PAFR mRNA expression in airway epithelial cells in human
lung tissue. On the other hand, we previously found an
increased proportion of PAFR-positive airway epithelial
cells in smokers without airway obstruction [10]. Immuno-
staining of the limited number of biopsy samples in the
present study found that PAFR is expressed by airway
epithelial cells e confirming our previous findings and
extending this to both goblet cells and bronchial submu-
cosal glands.
The variability of PAFR immunostaining in smokers and
smokers with COPD, and the small amounts of stored tissue
meant that quantification of cell-specific expression would
be biased and was therefore not done. However qualitative
analysis showed that most PAFR-positive cells were either
located at the bronchial surface (epithelial cells and goblet
cells) or lining submucosal glands that open into the airway.
It is therefore likely that these cells are major contributors
to increased PAFR mRNA expression in smokers and smokers
with COPD. Indeed, in vitro studies report a close associa-
tion between upregulation of PAFR mRNA expression in
epithelial cells and both surface PAFR expression and PAFR-
dependent bacterial adhesion [8,18]. Our data suggest that
future studies of PAFR-dependent adhesion should focus on
goblet and bronchial submucosal cells. Indeed in a guinea
pig model of COPD, an increase in the number of airway
goblet cells induced by chronic exposure to cigarette smoke
is significantly attenuated by treatment with a specific
antagonist of PAFR [20]. Whether increased endobronchial
PAFR mRNA expression in smokers and smokers with COPD
increases their capacity to support pneumococcal adhesion
is unclear. Indirect evidence of the functional relevance of
PAFR is provided by the observation of increased adherence
of pneumococci to buccal and pharyngeal epithelial cells in
smokers [21,22]. In COPD however, pneumococcal adher-
ence to bronchial epithelial and oropharyngeal cells is not
increased [23].
RV infection increases PAFR expression and PAFR-
dependent adhesion of S. pneumoniae to nasal epithelial
cells [24] and human tracheal epithelial cells in vitro [9].
The present study is the first study to evaluate the effect of
RV infection on PAFR expression in vivo. Following RV16
infection we found no increase in PAFR mRNA in COPD
subjects, smokers or non-smoking controls. There was
however, a trend towards increased PAFR in the RV-
infected non-smoking controls, (p Z 0.09). Although
these data do not support our hypothesis that RV infection
increases PAFR mRNA, the limited number of subjects
studied means an effect of RV infection cannot be excluded
e especially in controls. Future studies should therefore
include larger subject numbers, and additional time points.
Both experimental [13] and naturally-acquired RV in-
fections in patients with COPD are associated with not only
S. pneumoniae but also other bacteria such as H. influenzae
[26]. Although H. influenzae can utilise PAFR it also binds to
host cells via a number of other receptors including carci-
noembryonic antigen cell adhesion molecules 1 and 3,
Figure 4 Platelet-activating factor receptor (PAFR) mRNA
expression at day 7 in endobronchial tissue in subjects who
developed a rhinovirus infection. PAFR was measured by
quantitative PCR and expressed relative to the house-keeping
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
There is no significant differences between groups (p Z NS,
Dunnett’s multiple comparisons test). Bar represents mean.
Bronchial PAFR in COPD 903fibronectin, laminin, intercellular adhesion molecule-1 and
respiratory epithelial mucins [19]. The effects of RV
infection on these cellular receptors therefore warrant
further study to investigate their role in post-RV secondary
infections due to H. influenzae. The discrepancies between
the in vitro and in vivo effects of RV on PAFR highlight the
importance of carrying out such studies in vivo in COPD
subjects.
In conclusion, the study found that endobronchial PAFR
mRNA expression is increased in both smokers and smokers
with COPD compared with healthy controls, and that RV16
infection does not further increase PAFR mRNA. Immuno-
histochemical analysis showed PAFR-positive cells pre-
dominately located at the bronchial air-tissue interface.
These data suggest that blocking of PAFR by, for example,
second generation antihistamines [27], may reduce bacte-
rial adhesion to airway cells of smokers and smokers with
COPD.
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